カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界の神経障害薬市場2022年：抗精神病薬、催眠薬、鎮静薬、鎮痛薬、抗凝固薬、その他

◆英語タイトル：Global Neurological Disorder Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22MY8902）◆商品コード：GIR22MY8902
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2022年5月（※2025年版があります。お問い合わせください。）
◆ページ数：98
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

神経障害薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の神経障害薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

神経障害薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・抗精神病薬、催眠薬、鎮静薬、鎮痛薬、抗凝固薬、その他

用途別セグメントは次のように区分されます。
・病院、クリーム

世界の神経障害薬市場の主要な市場プレーヤーは以下のとおりです。
・Novartis、GlaxoSmithKline、Merck & Co.、Bayer、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceutical

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、神経障害薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な神経障害薬メーカーの企業概要、2019年～2022年までの神経障害薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な神経障害薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別神経障害薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの神経障害薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での神経障害薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および神経障害薬の産業チェーンを掲載しています。
・第13、14、15章では、神経障害薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Novartis、GlaxoSmithKline、Merck & Co.、Bayer、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceutical
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：抗精神病薬、催眠薬、鎮静薬、鎮痛薬、抗凝固薬、その他
・用途別分析2017年-2028年：病院、クリーム
・神経障害薬の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・神経障害薬のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・神経障害薬のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・神経障害薬の南米市場規模2017年-2028年：ブラジル、アルゼンチン
・神経障害薬の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Neurological Disorder Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neurological Disorder Drugs market size is estimated to be worth US$ 19820 million in 2021 and is forecast to a readjusted size of USD 25180 million by 2028 with a CAGR of 3.5% during review period. Hospital accounting for % of the Neurological Disorder Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Antipsychotic segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neurological Disorder Drugs include Novartis, GlaxoSmithKline, Merck & Co., Bayer, and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neurological Disorder Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Market segment by Application can be divided into
Hospital
Clinic
The key market players for global Neurological Disorder Drugs market are listed below:
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neurological Disorder Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neurological Disorder Drugs, with price, sales, revenue and global market share of Neurological Disorder Drugs from 2019 to 2022.
Chapter 3, the Neurological Disorder Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurological Disorder Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neurological Disorder Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurological Disorder Drugs.
Chapter 13, 14, and 15, to describe Neurological Disorder Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Neurological Disorder Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neurological Disorder Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Antipsychotic
1.2.3 Hypnotic & Sedative
1.2.4 Analgesics
1.2.5 Anticoagulants
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Neurological Disorder Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Neurological Disorder Drugs Market Size & Forecast
1.4.1 Global Neurological Disorder Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neurological Disorder Drugs Sales in Volume (2017-2028)
1.4.3 Global Neurological Disorder Drugs Price (2017-2028)
1.5 Global Neurological Disorder Drugs Production Capacity Analysis
1.5.1 Global Neurological Disorder Drugs Total Production Capacity (2017-2028)
1.5.2 Global Neurological Disorder Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neurological Disorder Drugs Market Drivers
1.6.2 Neurological Disorder Drugs Market Restraints
1.6.3 Neurological Disorder Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Neurological Disorder Drugs Product and Services
2.1.4 Novartis Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Neurological Disorder Drugs Product and Services
2.2.4 GlaxoSmithKline Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Merck & Co.
2.3.1 Merck & Co. Details
2.3.2 Merck & Co. Major Business
2.3.3 Merck & Co. Neurological Disorder Drugs Product and Services
2.3.4 Merck & Co. Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Neurological Disorder Drugs Product and Services
2.4.4 Bayer Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Neurological Disorder Drugs Product and Services
2.5.4 AstraZeneca Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Neurological Disorder Drugs Product and Services
2.6.4 Boehringer Ingelheim Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Teva Pharmaceutical
2.7.1 Teva Pharmaceutical Details
2.7.2 Teva Pharmaceutical Major Business
2.7.3 Teva Pharmaceutical Neurological Disorder Drugs Product and Services
2.7.4 Teva Pharmaceutical Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Neurological Disorder Drugs Breakdown Data by Manufacturer
3.1 Global Neurological Disorder Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neurological Disorder Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neurological Disorder Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Neurological Disorder Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Neurological Disorder Drugs Manufacturer Market Share in 2021
3.5 Global Neurological Disorder Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neurological Disorder Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neurological Disorder Drugs Market Size by Region
4.1.1 Global Neurological Disorder Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Neurological Disorder Drugs Revenue by Region (2017-2028)
4.2 North America Neurological Disorder Drugs Revenue (2017-2028)
4.3 Europe Neurological Disorder Drugs Revenue (2017-2028)
4.4 Asia-Pacific Neurological Disorder Drugs Revenue (2017-2028)
4.5 South America Neurological Disorder Drugs Revenue (2017-2028)
4.6 Middle East and Africa Neurological Disorder Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Neurological Disorder Drugs Sales in Volume by Type (2017-2028)
5.2 Global Neurological Disorder Drugs Revenue by Type (2017-2028)
5.3 Global Neurological Disorder Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Neurological Disorder Drugs Sales in Volume by Application (2017-2028)
6.2 Global Neurological Disorder Drugs Revenue by Application (2017-2028)
6.3 Global Neurological Disorder Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Neurological Disorder Drugs Sales by Type (2017-2028)
7.2 North America Neurological Disorder Drugs Sales by Application (2017-2028)
7.3 North America Neurological Disorder Drugs Market Size by Country
7.3.1 North America Neurological Disorder Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Neurological Disorder Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Neurological Disorder Drugs Sales by Type (2017-2028)
8.2 Europe Neurological Disorder Drugs Sales by Application (2017-2028)
8.3 Europe Neurological Disorder Drugs Market Size by Country
8.3.1 Europe Neurological Disorder Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Neurological Disorder Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Neurological Disorder Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Neurological Disorder Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Neurological Disorder Drugs Market Size by Region
9.3.1 Asia-Pacific Neurological Disorder Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neurological Disorder Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Neurological Disorder Drugs Sales by Type (2017-2028)
10.2 South America Neurological Disorder Drugs Sales by Application (2017-2028)
10.3 South America Neurological Disorder Drugs Market Size by Country
10.3.1 South America Neurological Disorder Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Neurological Disorder Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neurological Disorder Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Neurological Disorder Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Neurological Disorder Drugs Market Size by Country
11.3.1 Middle East & Africa Neurological Disorder Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neurological Disorder Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Neurological Disorder Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neurological Disorder Drugs
12.3 Neurological Disorder Drugs Production Process
12.4 Neurological Disorder Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neurological Disorder Drugs Typical Distributors
13.3 Neurological Disorder Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Neurological Disorder Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neurological Disorder Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Novartis Basic Information, Manufacturing Base and Competitors
Table 4. Novartis Major Business
Table 5. Novartis Neurological Disorder Drugs Product and Services
Table 6. Novartis Neurological Disorder Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline Major Business
Table 9. GlaxoSmithKline Neurological Disorder Drugs Product and Services
Table 10. GlaxoSmithKline Neurological Disorder Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 12. Merck & Co. Major Business
Table 13. Merck & Co. Neurological Disorder Drugs Product and Services
Table 14. Merck & Co. Neurological Disorder Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Bayer Basic Information, Manufacturing Base and Competitors
Table 16. Bayer Major Business
Table 17. Bayer Neurological Disorder Drugs Product and Services
Table 18. Bayer Neurological Disorder Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 20. AstraZeneca Major Business
Table 21. AstraZeneca Neurological Disorder Drugs Product and Services
Table 22. AstraZeneca Neurological Disorder Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 24. Boehringer Ingelheim Major Business
Table 25. Boehringer Ingelheim Neurological Disorder Drugs Product and Services
Table 26. Boehringer Ingelheim Neurological Disorder Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 28. Teva Pharmaceutical Major Business
Table 29. Teva Pharmaceutical Neurological Disorder Drugs Product and Services
Table 30. Teva Pharmaceutical Neurological Disorder Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Global Neurological Disorder Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 32. Global Neurological Disorder Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 33. Market Position of Manufacturers in Neurological Disorder Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 34. Global Neurological Disorder Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Neurological Disorder Drugs Production Site of Key Manufacturer
Table 36. Neurological Disorder Drugs New Entrant and Capacity Expansion Plans
Table 37. Neurological Disorder Drugs Mergers & Acquisitions in the Past Five Years
Table 38. Global Neurological Disorder Drugs Sales by Region (2017-2022) & (K Units)
Table 39. Global Neurological Disorder Drugs Sales by Region (2023-2028) & (K Units)
Table 40. Global Neurological Disorder Drugs Revenue by Region (2017-2022) & (USD Million)
Table 41. Global Neurological Disorder Drugs Revenue by Region (2023-2028) & (USD Million)
Table 42. Global Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 43. Global Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 44. Global Neurological Disorder Drugs Revenue by Type (2017-2022) & (USD Million)
Table 45. Global Neurological Disorder Drugs Revenue by Type (2023-2028) & (USD Million)
Table 46. Global Neurological Disorder Drugs Price by Type (2017-2022) & (USD/Unit)
Table 47. Global Neurological Disorder Drugs Price by Type (2023-2028) & (USD/Unit)
Table 48. Global Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 49. Global Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 50. Global Neurological Disorder Drugs Revenue by Application (2017-2022) & (USD Million)
Table 51. Global Neurological Disorder Drugs Revenue by Application (2023-2028) & (USD Million)
Table 52. Global Neurological Disorder Drugs Price by Application (2017-2022) & (USD/Unit)
Table 53. Global Neurological Disorder Drugs Price by Application (2023-2028) & (USD/Unit)
Table 54. North America Neurological Disorder Drugs Sales by Country (2017-2022) & (K Units)
Table 55. North America Neurological Disorder Drugs Sales by Country (2023-2028) & (K Units)
Table 56. North America Neurological Disorder Drugs Revenue by Country (2017-2022) & (USD Million)
Table 57. North America Neurological Disorder Drugs Revenue by Country (2023-2028) & (USD Million)
Table 58. North America Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 59. North America Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 60. North America Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 61. North America Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 62. Europe Neurological Disorder Drugs Sales by Country (2017-2022) & (K Units)
Table 63. Europe Neurological Disorder Drugs Sales by Country (2023-2028) & (K Units)
Table 64. Europe Neurological Disorder Drugs Revenue by Country (2017-2022) & (USD Million)
Table 65. Europe Neurological Disorder Drugs Revenue by Country (2023-2028) & (USD Million)
Table 66. Europe Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 67. Europe Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 68. Europe Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 69. Europe Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 70. Asia-Pacific Neurological Disorder Drugs Sales by Region (2017-2022) & (K Units)
Table 71. Asia-Pacific Neurological Disorder Drugs Sales by Region (2023-2028) & (K Units)
Table 72. Asia-Pacific Neurological Disorder Drugs Revenue by Region (2017-2022) & (USD Million)
Table 73. Asia-Pacific Neurological Disorder Drugs Revenue by Region (2023-2028) & (USD Million)
Table 74. Asia-Pacific Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 75. Asia-Pacific Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 76. Asia-Pacific Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 77. Asia-Pacific Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 78. South America Neurological Disorder Drugs Sales by Country (2017-2022) & (K Units)
Table 79. South America Neurological Disorder Drugs Sales by Country (2023-2028) & (K Units)
Table 80. South America Neurological Disorder Drugs Revenue by Country (2017-2022) & (USD Million)
Table 81. South America Neurological Disorder Drugs Revenue by Country (2023-2028) & (USD Million)
Table 82. South America Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 83. South America Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 84. South America Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 85. South America Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 86. Middle East & Africa Neurological Disorder Drugs Sales by Region (2017-2022) & (K Units)
Table 87. Middle East & Africa Neurological Disorder Drugs Sales by Region (2023-2028) & (K Units)
Table 88. Middle East & Africa Neurological Disorder Drugs Revenue by Region (2017-2022) & (USD Million)
Table 89. Middle East & Africa Neurological Disorder Drugs Revenue by Region (2023-2028) & (USD Million)
Table 90. Middle East & Africa Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 91. Middle East & Africa Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 92. Middle East & Africa Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 93. Middle East & Africa Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 94. Neurological Disorder Drugs Raw Material
Table 95. Key Manufacturers of Neurological Disorder Drugs Raw Materials
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Neurological Disorder Drugs Typical Distributors
Table 99. Neurological Disorder Drugs Typical Customers
List of Figures
Figure 1. Neurological Disorder Drugs Picture
Figure 2. Global Neurological Disorder Drugs Revenue Market Share by Type in 2021
Figure 3. Antipsychotic
Figure 4. Hypnotic & Sedative
Figure 5. Analgesics
Figure 6. Anticoagulants
Figure 7. Others
Figure 8. Global Neurological Disorder Drugs Revenue Market Share by Application in 2021
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Global Neurological Disorder Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Neurological Disorder Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Neurological Disorder Drugs Sales (2017-2028) & (K Units)
Figure 14. Global Neurological Disorder Drugs Price (2017-2028) & (USD/Unit)
Figure 15. Global Neurological Disorder Drugs Production Capacity (2017-2028) & (K Units)
Figure 16. Global Neurological Disorder Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Neurological Disorder Drugs Market Drivers
Figure 18. Neurological Disorder Drugs Market Restraints
Figure 19. Neurological Disorder Drugs Market Trends
Figure 20. Global Neurological Disorder Drugs Sales Market Share by Manufacturer in 2021
Figure 21. Global Neurological Disorder Drugs Revenue Market Share by Manufacturer in 2021
Figure 22. Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Neurological Disorder Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Neurological Disorder Drugs Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Neurological Disorder Drugs Sales Market Share by Region (2017-2028)
Figure 26. Global Neurological Disorder Drugs Revenue Market Share by Region (2017-2028)
Figure 27. North America Neurological Disorder Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Europe Neurological Disorder Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Neurological Disorder Drugs Revenue (2017-2028) & (USD Million)
Figure 30. South America Neurological Disorder Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Neurological Disorder Drugs Revenue (2017-2028) & (USD Million)
Figure 32. Global Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 33. Global Neurological Disorder Drugs Revenue Market Share by Type (2017-2028)
Figure 34. Global Neurological Disorder Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 35. Global Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 36. Global Neurological Disorder Drugs Revenue Market Share by Application (2017-2028)
Figure 37. Global Neurological Disorder Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 38. North America Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 39. North America Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 40. North America Neurological Disorder Drugs Sales Market Share by Country (2017-2028)
Figure 41. North America Neurological Disorder Drugs Revenue Market Share by Country (2017-2028)
Figure 42. United States Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 46. Europe Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 47. Europe Neurological Disorder Drugs Sales Market Share by Country (2017-2028)
Figure 48. Europe Neurological Disorder Drugs Revenue Market Share by Country (2017-2028)
Figure 49. Germany Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Neurological Disorder Drugs Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Neurological Disorder Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Neurological Disorder Drugs Revenue Market Share by Region (2017-2028)
Figure 58. China Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 65. South America Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 66. South America Neurological Disorder Drugs Sales Market Share by Country (2017-2028)
Figure 67. South America Neurological Disorder Drugs Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Neurological Disorder Drugs Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Neurological Disorder Drugs Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Neurological Disorder Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Neurological Disorder Drugs in 2021
Figure 79. Manufacturing Process Analysis of Neurological Disorder Drugs
Figure 80. Neurological Disorder Drugs Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の神経障害薬市場2022年：抗精神病薬、催眠薬、鎮静薬、鎮痛薬、抗凝固薬、その他(Global Neurological Disorder Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 前頭側頭型認知症治療薬のグローバル市場2023年：抗うつ剤、抗精神病薬
  • 循環器疾患看護薬のグローバル市場2023年：降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬
  • 世界の双極性障害薬＆治療市場インサイト及び予測（気分安定薬、抗けいれん薬、抗精神病薬、抗うつ薬、抗不安薬）
  • 世界の自殺防止治療薬市場2022年：抗うつ薬・抗不安薬、抗精神病薬、NMDA拮抗薬、抗生物質類似化合物、その他
  • 世界の慢性心不全(CHF)治療薬市場2022年：抗凝固薬（アスピリン）、抗血小板薬（クロピドグレル、プラスグレル、チカグレロル）、抗凝固薬（ワルファリン）、血圧維持薬（アンジオテンシン変換酵素（ACE）阻害剤）、アンジオテンシンII受容体遮断薬（ARB）、スタチン、利尿薬、硝酸塩